Epigenetic inhibitors with PARPis: A novel therapeutic strategy for BRCA-proficient pancreatic cancer

Patient-derived pancreatic cancer organoids showed significant growth inhibition when treated with decitabine, an epigenetic inhibitor. Noticeably, the combination of decitabine with a PARP inhibitor showed pronounced synergism in inhibiting tumour organoid growth.

By employing the 6-base genome via duet evoC, researchers at the University of Maryland have identified differentially methylated genes that may be responsible for therapy resistance and tumor aggression in pancreatic cancer.